Aclarion, Inc.

NasdaqCM ACON

Aclarion, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

Aclarion, Inc. Net Cash Used For Investing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqCM: ACON

Aclarion, Inc.

CEO	Mr. Brent Ness
IPO Date	April 22, 2022
Location	United States
Headquarters	951 Mariners Island Boulevard
Employees	4
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Database Medical Instruments Pharmaceuticals Software-as-a-Service (SaaS) Telehealth

Description

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Key trends

Past 5 years